Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has taken a significant step toward expanding its oncology pipeline by entering into a non-binding letter of intent (LOI) with Ifowonco Informatics Incorporated. The LOI is the initial phase in negotiating a definitive agreement that, if finalized, would grant Onco an exclusive option on Ifowonco's proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (LAG-3), a key immune checkpoint protein.
This potential collaboration aims to merge Ifowonco's oral small-molecule immune checkpoint technology with Onco-Innovations' expertise in DNA damage response (DDR) therapeutics, translational oncology, and clinical development. The companies believe that combining DDR inhibition with LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications.
Ifowonco's program is focused on developing orally available small-molecule LAG-3 inhibitors, a departure from currently approved LAG-3 therapies that are administered intravenously as monoclonal antibodies. This oral approach could offer advantages in patient convenience and potentially broader application. The companies intend to evaluate the LAG-3 program independently and, where supported by preclinical findings, explore its use alongside DDR-based therapeutic approaches, including Onco-Innovations' ONC010 program.
CEO Thomas O'Shaughnessy remarked that the potential agreement could position the company "at the intersection of precision oncology and next-generation cancer immunotherapy." This strategic move aligns with Onco's mission to pursue the prevention and treatment of cancer through pioneering research and innovative solutions.
The news is important as it highlights a growing trend in cancer treatment: combining different therapeutic modalities to improve efficacy. LAG-3 inhibitors are a relatively new class of immunotherapies, and oral small-molecule versions could be more convenient than current intravenous monoclonal antibody treatments. If successful, the combination of DDR inhibitors and LAG-3 blockade could provide new options for patients with solid tumours that are resistant to existing therapies.
Onco-Innovations, a Canadian-based company, has secured an exclusive worldwide license to patented technology that targets solid tumours, underscoring its commitment to advancing cancer care. The company's latest news and updates are available in its newsroom at https://ibn.fm/ONNVF.
For the full press release, visit https://ibn.fm/E63Ne. This development also underscores the active innovation in the biotech sector, with companies like Onco-Innovations and Ifowonco pushing the boundaries of cancer immunotherapy.
